Presence and Impact of Neuropsychiatric Symptoms in Preclinical Alzheimer’s Disease
This TLR found that changes in mood, including apathy, depression, and anxiety are frequently reported in preclinical AD. While less common, agitation and irritability were reported in >30% of studies reviewed. As expected, the reported impact of mood and other NPS on daily function in preclinical AD was low. Additional research can provide insight into selection and implementation of fit-for-purpose COAs to evaluate the potential impact of treatment on onset and progression of NPS in preclinical AD.
Authors
- Yuma Yokoi (ORCID: https://orcid.org/0000-0002-4405-8322)
- Nalin Payakachat (ORCID: https://orcid.org/0000-0002-9526-5356)
- Zachary T. Sheff (ORCID: https://orcid.org/0000-0002-1126-5712)
- Kaelyn Rupinski
- Alexandra S. Atkins
- Ariana Buterbaugh
- E. Jolanda Muenzel
- Madeline Tallarico
Institutions
- Eli Lilly (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- Eli Lilly (Japan) (JP)
- Adelphi Laboratory Center (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108543
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00